Literature DB >> 11237899

The profile of repeated corneal transplantation.

V Bersudsky1, T Blum-Hareuveni, U Rehany, S Rumelt.   

Abstract

PURPOSE: To evaluate the primary indications for corneal transplantation in patients with repeated keratoplasties, graft survival, the causes and risk factors for failure.
SETTING: Tertiary referral care center.
DESIGN: Retrospective, noncomparative case series.
METHODS: Charts of all patients who underwent repeated corneal transplantation between 1985 and 1998 were reviewed. Eighty patients underwent repeated corneal transplantation, of which six underwent repeated corneal transplantation in both eyes, totaling 86 eyes. A total of 208 keratoplasties were performed in this group; 86 primary and 122 repeated keratoplasties. The most common primary indications for corneal transplantation were vascularized corneal scar in 31 of the 86 eyes (36%), followed by pseudophakic and aphakic bullous keratopathy (PBK, ABK). Of the repeated transplants, 55 eyes (64%) had one repeated graft, 27 eyes (31.4%) had two repeated grafts, three (3.5%) had three repeated grafts, and one (1.2%) had four repeated transplants. MAIN OUTCOME MEASURES: Final visual outcome and clarity of corneal graft.
RESULTS: At the end of the follow-up period, 44 of the 86 eyes (51%) had clear grafts, but only 39.5% had good visual outcome. The mean survival periods of the repeated transplants decreased gradually with the number of regrafting procedures, from 14.3 to 8.7 months. The mean survival period was longer for patients with ABK, PBK, and secondary glaucoma, and shorter for patients who experienced graft ulcer or surface disorders. Graft failure was unrelated to graft size, but was associated with vascularization (P = 0.025), additional surgical procedures (P < 0.0001), and postoperative complications (P < 0.0001). There was a constant tendency for decrease in visual acuity with time. Final visual acuity was 20/20 to 20/40 in 13 of the 86 eyes (15%), 20/80 to 20/200 in 23 eyes (27%), and less than 20/200 in 50 eyes (58%). The most common complication was immune rejection, which occurred in 65 of the 208 transplants (31%), followed by secondary glaucoma in 48 eyes (23%) and cataract in 19 eyes (9%). Graft survival decreased remarkably after the third and forth regrafts, to 25% and 0%, respectively, compared with the first and second regrafts, 37% and 43%, respectively.
CONCLUSIONS: "High-risk" preoperative conditions, postoperative complications, and the need for additional surgical interventions may decrease graft survival. Close follow-up, extended use of antiinflammatory, antiviral, and immunosuppressive drugs, and avoiding additional surgical interventions as much as possible may decrease graft failure and the need for repeated keratoplasties.

Entities:  

Mesh:

Year:  2001        PMID: 11237899     DOI: 10.1016/s0161-6420(00)00544-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  30 in total

1.  Systemic cyclosporin A in high failure risk, repeated corneal transplantation.

Authors:  S Rumelt; V Bersudsky; T Blum-Hareuveni; U Rehany
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

2.  Boston type 1 keratoprosthesis: the New York Eye and Ear experience.

Authors:  A P Patel; E I Wu; D C Ritterband; J A Seedor
Journal:  Eye (Lond)       Date:  2011-12-16       Impact factor: 3.775

3.  Comparison of outcomes of penetrating keratoplasty versus Descemet's stripping automated endothelial keratoplasty for penetrating keratoplasty graft failure due to corneal edema.

Authors:  Anna S Kitzmann; George R Wandling; John E Sutphin; Kenneth M Goins; Michael D Wagoner
Journal:  Int Ophthalmol       Date:  2012-01-22       Impact factor: 2.031

4.  Repeat penetrating keratoplasty: indications, graft survival, and visual outcome.

Authors:  H Al-Mezaine; M D Wagoner
Journal:  Br J Ophthalmol       Date:  2006-03       Impact factor: 4.638

5.  Persistent epithelial defects and ulcers in repeated corneal transplantation: incidence, causative agents, predisposing factors and treatment outcomes.

Authors:  Shimon Rumelt; Valery Bersudsky; Tami Blum-Hareuveni; Uri Rehany
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-05-24       Impact factor: 3.117

6.  Update on the Management of High-Risk Penetrating Keratoplasty.

Authors:  Sayena Jabbehdari; Alireza Baradaran Rafii; Ghasem Yazdanpanah; Pedram Hamrah; Edward J Holland; Ali R Djalilian
Journal:  Curr Ophthalmol Rep       Date:  2017-02-02

7.  Ocular surface rehabilitation: Application of human amniotic membrane in high-risk penetrating keratoplasties.

Authors:  Pho Nguyen; Kelly Rue; Martin Heur; Samuel C Yiu
Journal:  Saudi J Ophthalmol       Date:  2014-07-02

Review 8.  Indications, surgical procedures and outcomes of keratoplasty at a Tertiary University-based hospital: a review of 10 years' experience.

Authors:  Eman M Al-Sharif; Majed Alkharashi
Journal:  Int Ophthalmol       Date:  2021-02-24       Impact factor: 2.031

9.  The Boston Keratoprosthesis: comparing corneal epithelial cell compatibility with titanium and PMMA.

Authors:  Jared D Ament; Sandra J Spurr-Michaud; Claes H Dohlman; Ilene K Gipson
Journal:  Cornea       Date:  2009-08       Impact factor: 2.651

10.  Outcomes with the Boston Type 1 Keratoprosthesis at Instituto de Microcirugía Ocular IMO.

Authors:  Jose L Güell; Edilio Arcos; Oscar Gris; Diego Aristizabal; Miguel Pacheco; Claudia L Sanchez; Felicidad Manero
Journal:  Saudi J Ophthalmol       Date:  2011-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.